Pharmaceutical composition for treating and/or preventing cancer

A composition and drug technology, applied in the direction of drug combination, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve the problems of normal cell toxicity and side effects of antigens

Active Publication Date: 2018-05-29
TORAY IND INC
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has attracted attention as a cancer-specific therapeutic drug that has achieved certain efficacy, but most of the target antigen protein is also expressed in normal cells, and as a result of antibody administration, not only cancer cells but also normal cells expressing the antigen are poisoned, and the resulting side effects become problematic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating and/or preventing cancer
  • Pharmaceutical composition for treating and/or preventing cancer
  • Pharmaceutical composition for treating and/or preventing cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0074] Antigens can be prepared by, for example, a method using animal cells (JP 2007-530068) and / or a method using baculovirus (eg, International Publication No. WO98 / 46777, etc.). When the immunogenicity of the antigen is low, it can be combined with a macromolecule with immunogenicity such as albumin for immunization. Antigens can also be administered together with an adjuvant for immunization.

[0075]The antibody of the present invention can also be obtained as a genetically recombinant antibody produced by cloning its antibody gene from a hybridoma, integrating it into an appropriate vector, introducing it into a host, and using genetic recombination technology (see, for example, Carl, A.K. Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, the cDNA of the antibody variable region (V region) is synthesized from hybridoma mRNA using reverse transcriptase. If DNA encoding the...

Embodiment 1

[0168] CAPRIN-1 expression analysis in each tissue of embodiment 1

[0169] According to Example 1(4) of WO2010 / 016526, the expression of CAPRIN-1 gene in normal tissues and various cell lines of dogs and humans was examined by RT-PCR method. As a result, it was found that, for normal dog tissues, strong expression was found in the testis, and on the other hand, expression was found in dog mammary carcinoma and adenocarcinoma tissues. Furthermore, the expression in human tissues was confirmed at the same time. As a result, similar to the dog CAPRIN-1 gene, only the testis was confirmed to be expressed in normal tissues. For cancer cells, eight human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, MRK-nu-1) and 4 pancreatic cancer cell lines (Capan-2, MIAPaCa-2, Panc- 1, BxPc-3) and other cancer cell lines were detected to express. From these results, it was confirmed that CAPRIN-1 was not expressed in normal tissues other than the testi...

Embodiment 2

[0170] Example 2 Production of Mouse Monoclonal Antibody Against CAPRIN-1

[0171] (1) Preparation of mouse monoclonal antibody

[0172] 100 μg of the human CAPRIN-1 protein having the amino acid sequence of SEQ ID NO: 2 prepared in Example 3 of WO2010 / 016526 was mixed with an equal amount of MPL+TDM adjuvant (manufactured by Sigma Corporation), and the resulting mixture was used as a small mouse antigen solution. The antigen solution was intraperitoneally administered to 6-week-old Balb / cc mice (manufactured by Japan SLC), and then administered seven times every week to complete immunization. Each spleen extracted 3 days after the last immunization was sandwiched between two sterilized glass slides and ground, washed with PBS (-) (manufactured by Nissui Co., Ltd.), centrifuged at 1500 rpm for 10 minutes, and The operation of removing the supernatant was repeated three times to obtain spleen cells. The obtained spleen cells were mixed with mouse myeloma cells SP2 / 0 (purchas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an antibody targeting a cancer antigen protein specifically expressed on the surface of cancer cells and its use as a therapeutic and / or preventive agent for cancer. Specifically, it provides an antibody containing the amino acid sequence shown in SEQ ID NO: 5. or an antibody or fragment thereof that is immunoreactive with the CAPRIN-1 partial polypeptide of the amino acid sequence having 80% or more sequence identity with the amino acid sequence; Pharmaceutical composition for treatment and / or prophylaxis.

Description

technical field [0001] The present invention relates to a novel medical use of an antibody against CAPRIN-1 or a fragment thereof as a therapeutic and / or preventive agent for cancer. Background technique [0002] Cancer is the number one cause of death among all diseases, and the current treatment is mainly surgery, combined with radiotherapy and chemotherapy. Despite the development of new surgical methods and the discovery of new anticancer agents in recent years, the results of cancer treatment have not improved much except for some cancers. In recent years, with the advancement of molecular biology and cancer immunology, antibodies that specifically react with cancer, cancer antigens recognized by cytotoxic T cells, and genes encoding cancer antigens have been identified. Anticipation of class-specific cancer therapy is increasing (Non-Patent Document 1). [0003] In cancer therapy methods, in order to reduce side effects, it is desirable that a peptide, polypeptide or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/30A61K39/395A61P35/00C12N15/09C12P21/08
CPCC07K16/30C07K2317/24C07K2317/732C07K16/28C07K2317/34A61P35/00A61P35/02A61P43/00A61K39/3955C07K16/18A61K2039/505
Inventor 小林真一冈野文义斋藤孝则
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap